What are the emerging molecular targets for cancer therapy?
Advances in understanding the molecular basis of cancer have led to the development of targeted therapies. These therapies specifically inhibit the function of mutated proteins or dysregulated pathways in cancer cells. Examples include tyrosine kinase inhibitors like imatinib for BCR-ABL in CML, HER2 inhibitors like trastuzumab for HER2-positive breast cancer, and immune checkpoint inhibitors targeting PD-1 or CTLA-4 in various cancers.
